Recent Blog Posts

View Post: Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and ...
6 Nov 2009 by Quintas-Cardama, Kantarjian, Manshouri,...  
Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera. Alfonso Quintás-Cardama, Hagop Kantarjian, Taghi Manshouri, ...
View Blog: Journal of Clinical Oncology Current Issue - http://jco.ascopubs.org/

---

View Post: CIENCIASMEDICASNEWS: Medication Guides
21 Nov 2009 by salud equitativa  
Roferon-A* (interferon alfa-2a recombinant) [2008 version] Rozerem (ramelteon) [2008 version] Sabril (vigabatrin) [2009 version] Sarafem (fluoxetine hydrochloride) [2007 version] Savella (milnacipran hydrochloride) [2009 version] ...
View Blog: CIENCIASMEDICASNEWS - http://elbiruniblogspotcom.blogspot.com/

---

View Post: Liver Cirrhosis Clinical Trial: Retreatment With High Doses of ...
28 Oct 2009
Official Title: “Efficacy of High Doses of Both Pegylated Interferon Alfa-2a and Ribavirin for Retreatment of HIV-coinfected Patients With Liver Cirrhosis Due to HCV Genotype 1 or 4 Nonresponders to Previous Standard Therapy.” ...
View Blog: Clinical Trials Updates During the Last 7 Days - http://clinicaltrialsfeeds.org/clinical-trials/r...

---

View Post: Merimepodib, pegylated interferon, and ribavirin in genotype 1 ...
24 Oct 2009 by Rustgi VK, Lee WM, Lawitz E, Gordon SC,...  
Merimepodib (MMPD) is an orally administered, inosine monophosphate dehydrogenase inhibitor that has shown antiviral activity in nonresponders with chronic hepatitis C (CHC) when combined with pegylated interferon alfa 2a ...
View Blog: JournalFeeds - http://journalfeeds.com/

---

View Post: Management of chronic hepatitis C patients who have relapsed or ...
8 Nov 2009 by JOC  
In the REPEAT trial, the sustained response rate was significantly higher in nonresponders to pegylated interferon alfa-2b (12 kD) plus ribavirin randomized to 72 weeks of peginterferon alfa-2a (40 kD) plus ribavirin, compared with a ...
View Blog: InfectoNews - Jorge Omar Calabrese - http://infectonews.wordpress.com/

---

View Post: Cancer Journal: Latest cancer research Bevacizumab (Avastin) in ...
4 Sep 2009
The study compared the combination of bevacizumab plus interferon alfa-2a to interferon alfa-2a plus placebo. This trial was conducted by Hoffmann-La-Roche in Europe, Asia, and Australia. The primary outcome measure of the trial, ...
View Blog: ecancer news - http://www.ecancermedicalscience.com/

---

View Post: Other Drugs for BMS I Exam 3 / Flashcards - Create Free Flashcards
5 Nov 2009 by s-tedrick@onu.edu  
Interferon alfa-n3, human leukocyte derived (not recombinant)-natural... 3. Interferon alfacon-1, recombinant, consensus interferon-Produced... 13. Peginterferon alfa 2a, -pegylated so longer half life (once weekly. ...
View Blog: ProProfs Flashcards - http://www.proprofs.com/flashcards/

---

View Post: Roche and Pharmasset, Inc. Initiate Phase IIb Clinical Trial of ...
27 Apr 2009
The trial will evaluate the dose and duration of treatment of R7128 in combination with Roche's PEGASYS(R) (peginterferon alfa-2a) and COPEGUS(R) (ribavirin) - in HCV patients who have not been treated previously. .... Ischemic and hemorrhagic cerebrovascular events have been observed in patients treated with interferon alfa-based therapies, including PEGASYS. Events occurred in patients with few or no reported risk factors for stroke, including patients less than 45 ...
View Blog: BioSpace.com Featured News and Stories - http://www.biospace.com/

---